UA75393C2 - Chimeric monoclonal antibody, identifying gangliosides containing n-glycolyl sialic acid, cells line producing it and pharmaceutical compositions containing it - Google Patents

Chimeric monoclonal antibody, identifying gangliosides containing n-glycolyl sialic acid, cells line producing it and pharmaceutical compositions containing it Download PDF

Info

Publication number
UA75393C2
UA75393C2 UA2003108989A UA2003108989A UA75393C2 UA 75393 C2 UA75393 C2 UA 75393C2 UA 2003108989 A UA2003108989 A UA 2003108989A UA 2003108989 A UA2003108989 A UA 2003108989A UA 75393 C2 UA75393 C2 UA 75393C2
Authority
UA
Ukraine
Prior art keywords
human
monoclonal antibody
antibodies
chain
mab
Prior art date
Application number
UA2003108989A
Other languages
English (en)
Ukrainian (uk)
Inventor
De Acosta Del Rio Christ Mateo
Navarro Lurdes Tatiana Roke
Original Assignee
Centro Inmunologia Molecular
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Centro Inmunologia Molecular filed Critical Centro Inmunologia Molecular
Publication of UA75393C2 publication Critical patent/UA75393C2/uk

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/42Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins
    • C07K16/4208Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7032Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a polyol, i.e. compounds having two or more free or esterified hydroxy groups, including the hydroxy group involved in the glycosidic linkage, e.g. monoglucosyldiacylglycerides, lactobionic acid, gangliosides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/739Lipopolysaccharides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/0005Vertebrate antigens
    • A61K39/0011Cancer antigens
    • A61K39/001169Tumor associated carbohydrates
    • A61K39/001171Gangliosides, e.g. GM2, GD2 or GD3
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39566Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against immunoglobulins, e.g. anti-idiotypic antibodies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/04Antineoplastic agents specific for metastasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/04Immunostimulants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3076Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3076Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties
    • C07K16/3084Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties against tumour-associated gangliosides
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/42Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins
    • C07K16/4208Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig
    • C07K16/4241Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig against anti-human or anti-animal Ig
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/42Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins
    • C07K16/4208Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig
    • C07K16/4241Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig against anti-human or anti-animal Ig
    • C07K16/4258Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig against anti-human or anti-animal Ig against anti-receptor Ig
    • C07K16/4266Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig against anti-human or anti-animal Ig against anti-receptor Ig against anti-tumor receptor Ig
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06Animal cells or tissues; Human cells or tissues
    • C12N5/0602Vertebrate cells
    • C12N5/0693Tumour cells; Cancer cells
    • C12N5/0694Cells of blood, e.g. leukemia cells, myeloma cells
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/577Immunoassay; Biospecific binding assay; Materials therefor involving monoclonal antibodies binding reaction mechanisms characterised by the use of monoclonal antibodies; monoclonal antibodies per se are classified with their corresponding antigens
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854Immunoglobulins
    • G01N33/686Anti-idiotype
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/505Medicinal preparations containing antigens or antibodies comprising antibodies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/555Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505Inorganic adjuvants
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/20Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565Complementarity determining region [CDR]
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567Framework region [FR]
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/70Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10Cells modified by introduction of foreign genetic material
    • C12N5/12Fused cells, e.g. hybridomas
    • C12N5/16Animal cells
    • C12N5/163Animal cells one of the fusion partners being a B or a T lymphocyte
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/70Mechanisms involved in disease identification
    • G01N2800/7023(Hyper)proliferation
    • G01N2800/7028Cancer
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407Specifically defined cancers
    • G01N33/57415Specifically defined cancers of breast

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Urology & Nephrology (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • General Engineering & Computer Science (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
UA2003108989A 2001-04-06 2002-08-04 Chimeric monoclonal antibody, identifying gangliosides containing n-glycolyl sialic acid, cells line producing it and pharmaceutical compositions containing it UA75393C2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CU2001008420010084A CU23007A1 (es) 2001-04-06 2001-04-06 Combinaciones inmunoterapéuticas para el tratamiencombinaciones inmunoterapéuticas para el tratamiento de tumores que sobre-expresan gangliósidos to de tumores que sobre-expresan gangliósidos
PCT/CU2002/000003 WO2002081496A2 (es) 2001-04-06 2002-04-08 Anticuerpos recombinantes asociados a gangliósidos. su uso en el diagnóstico y tratamiento de tumores

Publications (1)

Publication Number Publication Date
UA75393C2 true UA75393C2 (en) 2006-04-17

Family

ID=40291118

Family Applications (3)

Application Number Title Priority Date Filing Date
UA2003108988A UA76745C2 (uk) 2001-04-06 2002-08-04 Імунотерапевтичні комбінації для лікування пухлин, які надекспресують гангліозиди
UA2003108989A UA75393C2 (en) 2001-04-06 2002-08-04 Chimeric monoclonal antibody, identifying gangliosides containing n-glycolyl sialic acid, cells line producing it and pharmaceutical compositions containing it
UAA200512270A UA86768C2 (ru) 2001-04-06 2005-12-20 ХИМЕРНОЕ МОНОКЛОНАЛЬНОЕ АНТИТЕЛО, ПОЛУЧЕННОЕ ИЗ МЫШИНОГО АНТИИДИОТИПИЧНОГО МОНОКЛОНАЛЬНОГО АНТИТЕЛА 1Е10, КОТОРОЕ РАСПОЗНАЕТ МЫШИНОЕ MAbР3

Family Applications Before (1)

Application Number Title Priority Date Filing Date
UA2003108988A UA76745C2 (uk) 2001-04-06 2002-08-04 Імунотерапевтичні комбінації для лікування пухлин, які надекспресують гангліозиди

Family Applications After (1)

Application Number Title Priority Date Filing Date
UAA200512270A UA86768C2 (ru) 2001-04-06 2005-12-20 ХИМЕРНОЕ МОНОКЛОНАЛЬНОЕ АНТИТЕЛО, ПОЛУЧЕННОЕ ИЗ МЫШИНОГО АНТИИДИОТИПИЧНОГО МОНОКЛОНАЛЬНОГО АНТИТЕЛА 1Е10, КОТОРОЕ РАСПОЗНАЕТ МЫШИНОЕ MAbР3

Country Status (37)

Country Link
US (3) US20050069535A1 (es)
EP (3) EP1411064B1 (es)
JP (2) JP4366080B2 (es)
KR (3) KR100946168B1 (es)
CN (3) CN100349920C (es)
AR (2) AR033123A1 (es)
AT (3) ATE406386T1 (es)
AU (3) AU2002308348B2 (es)
BG (2) BG66304B1 (es)
BR (3) BR0208676B1 (es)
CA (2) CA2443372C (es)
CU (1) CU23007A1 (es)
CZ (2) CZ304424B6 (es)
DE (2) DE60223547T2 (es)
DK (2) DK1411064T3 (es)
EA (2) EA006310B1 (es)
EC (2) ECSP034788A (es)
ES (2) ES2296986T3 (es)
HK (3) HK1066818A1 (es)
HR (2) HRP20030806B1 (es)
HU (2) HU228105B1 (es)
IL (2) IL158246A0 (es)
IS (2) IS6965A (es)
MX (2) MXPA03008739A (es)
MY (3) MY137078A (es)
NO (2) NO331533B1 (es)
NZ (2) NZ528599A (es)
PE (1) PE20020972A1 (es)
PL (2) PL371770A1 (es)
PT (2) PT1384726E (es)
SG (1) SG161737A1 (es)
SI (2) SI1384726T1 (es)
SK (2) SK287914B6 (es)
UA (3) UA76745C2 (es)
UY (2) UY27242A1 (es)
WO (2) WO2002081496A2 (es)
ZA (2) ZA200307585B (es)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7297336B2 (en) * 2003-09-12 2007-11-20 Baxter International Inc. Factor IXa specific antibodies displaying factor VIIIa like activity
KR20070108536A (ko) * 2005-02-04 2007-11-12 수르벡 에이피에스 서바이빈 펩티드 백신
FI20055398A0 (fi) 2005-07-08 2005-07-08 Suomen Punainen Risti Veripalv Menetelmä solupopulaatioiden evaluoimiseksi
NZ595386A (en) * 2005-08-11 2013-08-30 Arpi Matossian Rogers Peptides for treatment and diagnosis of autoimmune disease
SI1915397T1 (sl) * 2005-08-19 2015-05-29 Wyeth Llc Antagonistična protitelesa proti GDF-8 in uporabe pri zdravljenju ALS in drugih obolenj, povezanih z GDF-8
ITFI20060163A1 (it) * 2006-06-29 2006-09-28 Menarini Internat Operations Luxembourg Sa Composizione farmaceutica contenente un anticorpo monoclonale anti idiotipico anti-ca-125 ed alluminio
TWI434855B (zh) 2006-11-21 2014-04-21 Hoffmann La Roche 結合物及其在免疫分析中作為參考標準之用途
EP2255787A4 (en) * 2008-02-22 2014-08-27 Katayama Chemical Ind Co Ltd SYNTHETIC LIPOSOMES CONTAINING GLYCOLIPIDS
EP2166085A1 (en) 2008-07-16 2010-03-24 Suomen Punainen Risti Veripalvelu Divalent modified cells
TWI445716B (zh) 2008-09-12 2014-07-21 Rinat Neuroscience Corp Pcsk9拮抗劑類
PL2406284T3 (pl) 2009-03-10 2017-09-29 Biogen Ma Inc. Przeciwciała anty-bcma
CA2757382A1 (en) 2009-04-01 2010-10-21 Kristi Elkins Anti-fcrh5 antibodies and immunoconjugates
CU23736A1 (es) * 2009-05-04 2011-11-15 Centro Inmunologia Molecular Anticuerpos que reconocen sulfatidos y proteoglicanos sulfatados y su uso
EP2473530B1 (en) * 2009-09-03 2015-04-22 Vancouver Biotech Ltd. Monoclonal antibodies against gonadotropin-releasing hormone receptor
CA2824389A1 (en) * 2011-01-10 2012-07-19 Emory University Antibodies directed against influenza
CU24070B1 (es) * 2011-12-27 2015-01-29 Ct De Inmunología Molecular Composiciones farmacéuticas para el tratamiento de tumores que expresan regf y gangliósidos n-glicolilados gm3 (neugcgm3)
EP2641916A1 (en) * 2012-03-23 2013-09-25 Centre National de la Recherche Scientifique (C.N.R.S) Novel antibodies anti-sPLA2-IIA and uses thereof
PE20150223A1 (es) 2012-06-15 2015-02-11 Pfizer Anticuerpos antagonistas mejorados contra factor-8 de crecimiento y diferenciacion y usos de los mismos
AR096687A1 (es) 2013-06-24 2016-01-27 Genentech Inc Anticuerpos anti-fcrh5
MX2016007958A (es) 2013-12-17 2016-08-03 Genentech Inc Anticuerpos anti-cd3 y metodos de uso.
RU2016138744A (ru) * 2014-04-10 2018-05-11 Оби Фарма Инк. Антитела, фармацевтические композиции и их применения
TWI715587B (zh) 2015-05-28 2021-01-11 美商安可美德藥物股份有限公司 Tigit結合劑和彼之用途
AR105026A1 (es) 2015-06-16 2017-08-30 Genentech Inc ANTICUERPOS MADURADOS POR AFINIDAD Y HUMANIZADOS PARA FcRH5 Y MÉTODOS PARA SU USO
WO2018017864A2 (en) * 2016-07-20 2018-01-25 Oncomed Pharmaceuticals, Inc. Pvrig-binding agents and uses thereof
NZ753515A (en) 2016-11-30 2022-02-25 Oncomed Pharm Inc Methods for treatment of cancer comprising tigit-binding agents
CU20170173A7 (es) * 2017-12-27 2019-11-04 Ct Inmunologia Molecular Nano-partículas que contienen el gangliósido gm3 como inmunomoduladoras

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2754206B2 (ja) * 1987-11-17 1998-05-20 メクト株式会社 α2→3結合を認識するモノクローナル抗体
US6051225A (en) * 1988-10-19 2000-04-18 The Dow Chemical Company Family of high affinity, modified antibodies for cancer treatment
ES2144440T3 (es) * 1992-08-18 2000-06-16 Centro Inmunologia Molecular Anticuerpos monoclonales que reconocen el receptor del factor de crecimiento epidermico, celulas y metodos para su produccion y compuestos que los contienen.
JPH07101999A (ja) * 1993-10-06 1995-04-18 Hagiwara Yoshihide 抗癌ヒトモノクローナル抗体に対する抗イデイオタイプ抗体のアミノ酸配列およびそれをコードするdna塩基配列
ES2166770T3 (es) * 1993-12-09 2002-05-01 Centro Inmunologia Molecular Anticuerpos monoclonales contra gangliosidos y sus utilizaciones en la inmunoterapia activa especifica de tumores malignos.
US6063379A (en) * 1993-12-09 2000-05-16 Centro De Inmunologia Molecular Anti-idiotypic monoclonal antibodies and compositions including the anti-idiotypic monoclonal antibodies
CU22702A1 (es) * 1997-10-21 2001-07-31 Centro Inmunologia Molecular Anticuerpos monoclonales anti - idiotipo, su uso en la inmunoterapia activa de tumores malignos, hibridoma que los produce y composiciones que los contienen
US6149921A (en) * 1993-12-29 2000-11-21 Centro De Inmunologia Molecular Vaccine compositions for eliciting an immune response against N-acetylated gangliosides and their use for cancer treatment
CU22420A1 (es) * 1993-12-29 1996-01-31 Centro Inmunologia Molecular Composicion vacunal para el desarrollo de una respuesta contra gangliosidos n glicolilados y su uso para el tratamiento del cancer
CU22615A1 (es) * 1994-06-30 2000-02-10 Centro Inmunologia Molecular Procedimiento de obtención de anticuerpos monoclonales murinos menos inmunogénicos. anticuerpos monoclonales obtenidos
CU22731A1 (es) * 1998-02-05 2002-02-28 Centro Inmunologia Molecular Anticuerpo monoclonal que reconoce el oligosacárido ácido siálico n´glicolilado-galactosa-glucosa (ngcneu-gal-glu) en tumores malignos y composiciones farmacéuticas que los contienen
US7442776B2 (en) * 1999-10-08 2008-10-28 Young David S F Cancerous disease modifying antibodies

Also Published As

Publication number Publication date
EA200301097A1 (ru) 2004-02-26
BG66304B1 (bg) 2013-03-29
BR0208675A (pt) 2004-08-03
SK12262003A3 (sk) 2004-08-03
UA76745C2 (uk) 2006-09-15
NZ528599A (en) 2005-03-24
EP1798243B1 (en) 2010-08-11
NO331533B1 (no) 2012-01-23
ATE477279T1 (de) 2010-08-15
ATE406386T1 (de) 2008-09-15
KR20030092048A (ko) 2003-12-03
SK12162003A3 (sk) 2004-05-04
EP1384726B1 (en) 2008-08-27
CN101054417B (zh) 2012-07-11
EP1798243A3 (en) 2007-10-17
SK287783B6 (sk) 2011-09-05
PT1384726E (pt) 2008-12-05
WO2002081496A2 (es) 2002-10-17
HU228106B1 (en) 2012-11-28
CA2443372A1 (en) 2002-10-17
US20100297008A1 (en) 2010-11-25
JP4366080B2 (ja) 2009-11-18
HUP0401355A3 (en) 2012-05-29
EP1411064B1 (en) 2007-11-14
BG108228A (bg) 2005-04-30
KR100863509B1 (ko) 2008-10-15
JP2004525953A (ja) 2004-08-26
US8758753B2 (en) 2014-06-24
CA2443372C (en) 2013-05-28
HK1066818A1 (es) 2005-04-01
MY137078A (en) 2008-12-31
CN1535282A (zh) 2004-10-06
KR20080080680A (ko) 2008-09-04
EP1798243A2 (en) 2007-06-20
KR100919617B1 (ko) 2009-09-29
HRP20030806B1 (en) 2011-11-30
HU228105B1 (en) 2012-11-28
DK1411064T3 (da) 2008-03-25
AR033123A1 (es) 2003-12-03
BG66293B1 (en) 2013-02-28
AR033122A1 (es) 2003-12-03
US20050069535A1 (en) 2005-03-31
KR20030087053A (ko) 2003-11-12
WO2002081661A2 (es) 2002-10-17
CN1319991C (zh) 2007-06-06
PL371937A1 (en) 2005-07-11
SK287914B6 (sk) 2012-03-02
CN101054417A (zh) 2007-10-17
HK1109160A1 (en) 2008-05-30
ATE378356T1 (de) 2007-11-15
MXPA03008739A (es) 2003-12-11
BG108227A (bg) 2005-04-30
ECSP034788A (es) 2004-01-28
IL158246A (en) 2010-05-31
MY145703A (en) 2012-03-30
CN100349920C (zh) 2007-11-21
UA86768C2 (ru) 2009-05-25
AU2007231687A1 (en) 2007-11-22
ES2296986T3 (es) 2008-05-01
ECSP034787A (es) 2004-01-28
ZA200307585B (en) 2004-09-16
ES2312610T3 (es) 2009-03-01
CZ20032641A3 (cs) 2004-07-14
CZ296276B6 (cs) 2006-02-15
CA2441845C (en) 2011-06-07
CU23007A1 (es) 2004-12-17
CA2441845A1 (en) 2002-10-17
SI1411064T1 (sl) 2008-04-30
MXPA03008738A (es) 2003-12-11
NO20034437L (no) 2003-12-02
BR0208676B1 (pt) 2017-11-14
NZ528598A (en) 2005-03-24
NO20034437D0 (no) 2003-10-03
CZ304424B6 (cs) 2014-04-30
HUP0401695A2 (en) 2006-08-28
NO20034436L (no) 2003-12-02
DE60223547T2 (de) 2008-09-18
EP1411064A2 (en) 2004-04-21
CZ20032668A3 (cs) 2004-07-14
AU2007231687B2 (en) 2010-09-30
BRPI0208675B1 (pt) 2018-03-13
EA200301098A1 (ru) 2004-04-29
SI1384726T1 (sl) 2009-04-30
EA006310B1 (ru) 2005-10-27
EA006936B1 (ru) 2006-06-30
HRP20030805B1 (en) 2011-11-30
IS2701B (is) 2010-11-15
HK1070080A1 (en) 2005-06-10
MY157372A (en) 2016-06-15
NO20034436D0 (no) 2003-10-03
PL208109B1 (pl) 2011-03-31
AU2002308348B2 (en) 2007-11-22
DE60223547D1 (de) 2007-12-27
UY27242A1 (es) 2002-07-31
ZA200307679B (en) 2005-03-30
WO2002081496A3 (es) 2004-02-19
BR0208676A (pt) 2008-04-08
AU2002308347B2 (en) 2006-09-14
UY27243A1 (es) 2002-09-30
IS6964A (is) 2003-09-23
PT1411064E (pt) 2008-02-12
HRP20030806A2 (en) 2005-08-31
US20040253233A1 (en) 2004-12-16
PE20020972A1 (es) 2003-01-02
IS6965A (is) 2003-09-23
DE60228561D1 (de) 2008-10-09
HUP0401355A2 (hu) 2004-10-28
EP1384726A2 (en) 2004-01-28
HUP0401695A3 (en) 2012-05-29
JP2004528033A (ja) 2004-09-16
IL158246A0 (en) 2004-05-12
KR100946168B1 (ko) 2010-03-11
WO2002081661A3 (es) 2003-01-03
DK1384726T3 (da) 2008-12-15
PL371770A1 (en) 2005-06-27
CN1507452A (zh) 2004-06-23
HRP20030805A2 (en) 2005-08-31
SG161737A1 (en) 2010-06-29

Similar Documents

Publication Publication Date Title
UA75393C2 (en) Chimeric monoclonal antibody, identifying gangliosides containing n-glycolyl sialic acid, cells line producing it and pharmaceutical compositions containing it
EP1623997B1 (en) Recombinant antibodies and fragments recognising ganglioside n-glycolyl-gm3 and use thereof in the diagnosis and treatment of tumours
UA125593C2 (uk) Антитіло в7-н3, його антигензв'язуючий фрагмент та його медичне застосування
MX2012015131A (es) Terapia contra el cancer que utiliza anticuerpos dirigidos a la cldn6 objetivo in vivo.
KR100301189B1 (ko) 당단백질피(p)에대한단일클론항체
JP5977936B2 (ja) 膵構造から誘導される糖ペプチド、抗体ならびに診断および治療におけるそれらの応用
US8617829B2 (en) Humanized antibodies specific for amino acid sequence RGD of an extracellular matrix protein and the uses thereof
KR20110005887A (ko) 세포 외 기질 단백질의 아미노산 서열 rgd에 특이적인 인간화된 항체 및 그의 용도
US7932043B2 (en) Use of monoclonal antibodies to distinguish protein conformational isoforms
JP5611210B2 (ja) 抗拡張i型スフィンゴ糖脂質抗体、その誘導体および使用
JP7010704B2 (ja) Aml抗原及びその使用
JPH02174691A (ja) モノクローナル抗体
Tomitaa et al. Generation of monoclonal antibodies directed against peptide sequences by a B cell targeting
JPS61238800A (ja) モノクロ−ナル抗体amf及びその製造法